EPS for Calithera Biosciences, Inc. (CALA) Expected At $-0.24; Lam Research (LRCX) Shorts Down By 5.51%

March 3, 2018 - By Marguerite Chambers

Analysts expect Calithera Biosciences, Inc. (NASDAQ:CALA) to report $-0.24 EPS on March, 15.They anticipate $0.21 EPS change or 46.67% from last quarter’s $-0.45 EPS. After having $-0.17 EPS previously, Calithera Biosciences, Inc.’s analysts see 41.18% EPS growth. The stock increased 3.23% or $0.25 during the last trading session, reaching $8. About 494,390 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since March 3, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Lam Research Corporation (NASDAQ:LRCX) had a decrease of 5.51% in short interest. LRCX’s SI was 10.39 million shares in March as released by FINRA. Its down 5.51% from 11.00 million shares previously. With 4.49 million avg volume, 2 days are for Lam Research Corporation (NASDAQ:LRCX)’s short sellers to cover LRCX’s short positions. The SI to Lam Research Corporation’s float is 6.44%. The stock increased 2.35% or $4.46 during the last trading session, reaching $194.53. About 2.78M shares traded. Lam Research Corporation (NASDAQ:LRCX) has risen 107.86% since March 3, 2017 and is uptrending. It has outperformed by 91.16% the S&P500.

Among 25 analysts covering Lam Research Corporation (NASDAQ:LRCX), 24 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Lam Research Corporation had 79 analyst reports since September 17, 2015 according to SRatingsIntel. On Monday, June 5 the stock rating was maintained by RBC Capital Markets with “Buy”. The rating was maintained by KeyBanc Capital Markets with “Buy” on Sunday, November 19. The rating was maintained by Needham on Thursday, January 26 with “Buy”. The firm has “Overweight” rating given on Thursday, March 16 by Pacific Crest. The rating was maintained by Susquehanna with “Neutral” on Monday, September 21. Credit Suisse maintained Lam Research Corporation (NASDAQ:LRCX) rating on Wednesday, October 18. Credit Suisse has “Buy” rating and $245.0 target. The stock of Lam Research Corporation (NASDAQ:LRCX) earned “Buy” rating by B. Riley & Co on Thursday, October 22. The firm has “Buy” rating by Stifel Nicolaus given on Monday, November 21. The rating was maintained by Citigroup with “Neutral” on Wednesday, October 18. The rating was maintained by Berenberg with “Buy” on Thursday, January 25.

Investors sentiment increased to 1.02 in 2017 Q3. Its up 0.04, from 0.98 in 2017Q2. It increased, as 51 investors sold Lam Research Corporation shares while 238 reduced holdings. 87 funds opened positions while 207 raised stakes. 146.35 million shares or 1.92% less from 149.22 million shares in 2017Q2 were reported. Guggenheim Cap Ltd Llc owns 708,580 shares. Meiji Yasuda Life Insurance Communication holds 14,565 shares or 0.4% of its portfolio. 7 were reported by Hwg Lp. Nomura Asset stated it has 217,314 shares. Oppenheimer And, a New York-based fund reported 8,341 shares. Shell Asset holds 24,769 shares. Alphaone Inv Services Ltd Liability accumulated 3,320 shares. Robeco Institutional Asset Mngmt Bv reported 162,847 shares stake. Bollard Gru Llc has 700 shares. Ubs Asset Mngmt Americas has invested 0.23% in Lam Research Corporation (NASDAQ:LRCX). Kentucky Retirement Ins Tru Fund invested in 4,265 shares. Dana Inv Inc has invested 2.05% in Lam Research Corporation (NASDAQ:LRCX). 3,635 are owned by Colony Group Incorporated Limited Co. Nikko Asset Management Americas Inc reported 800 shares stake. 35,150 are held by Eaton Vance Management.

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits worldwide. The company has market cap of $31.70 billion. The firm offers thin film deposition products, including SABRE electrochemical deposition products for copper damascene manufacturing; ALTUS systems to deposit conformal atomic layer films for tungsten metallization applications; VECTOR plasma-enhanced chemical vapor deposition and atomic layer deposition systems to deposit oxides, nitrides, and carbides for hardmasks, multiple patterning films, anti-reflective layers, multi-layer stack films, and diffusion barriers; and Striker atomic layer deposition systems that deliver conformal dielectric films for spacer patterning and liner applications in various advanced memory and logic structures. It has a 21.37 P/E ratio. The Company’s thin film deposition products also comprise SPEED high-density plasma CVD products for applications in shallow trench isolation, pre-metal dielectrics, inter-layer dielectrics, inter-metal dielectrics, and passivation layers; and SOLA ultraviolet thermal processing products for treatment of back-end-of-line (BEOL) low-k dielectric films and front-end-of-line silicon nitride strained films.

Since September 11, 2017, it had 0 insider purchases, and 11 insider sales for $12.77 million activity. NEWBERRY STEPHEN G had sold 750 shares worth $146,318 on Tuesday, October 17. ARCHER TIMOTHY had sold 8,691 shares worth $1.49M. 25,453 shares were sold by Varadarajan Seshasayee, worth $5.47M.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $283.81 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News